Inclusion Criteria

Concurrent Medication:

Allowed:

• Zidovudine (AZT).
• Didanosine (ddI).

Patients must have the following:

• Diagnosis of AIDS as defined by the CDC.
• Blood cultures positive for Mycobacterium avium complex or for acid-fast bacilli (AFB).
• Provide written informed consent.

Prior Medication:

Allowed:

• If receiving zidovudine (AZT) or ddI must be taking the medication for at least 4 weeks prior to study entry.
• Required:
• Antipneumocystis prophylactic therapy for at least 4 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Known hypersensitivity to any of the study drugs.

Concurrent Medication:

Excluded:

• Other therapy for mycobacterial disease.

Patients with the following are excluded:

• Known hypersensitivity to any of the study drugs.

Prior Medication:

Excluded within 4 weeks:

• Therapy for mycobacterial disease.
• Antiretroviral drugs, other than zidovudine (AZT) or ddI.
• Investigational drugs, other than ddI.